Newtyn Management
Newtyn Management reported 34 stocks worth $801M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are QDEL (14.5%), Theravance Biopharma Inc (7.3%) and INDV (6.7%). Compared with Q1 2026, the fund opened new positions in OCTV, PSIX and XRN, added to QDEL, MAGN and CCOI, trimmed INDV, CNNE and PAR and sold out of NVRI, VISN and USAR.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  QDEL Quidelortho Corp | $116M | 14.5% | 6.6M | +2.1M (+45%) | 8 of 8 | |
| 2 | THERAVANCE BIOPHARMA INC | $58.4M | 7.3% | 3.4M | −1.4M (−29%) | 8 of 8 | |
| 3 |  INDV Indivior PLC | $53.6M | 6.7% | 1.3M | −694K (−35%) | 2 of 8 | |
| 4 |  CNNE Cannae Hldgs Inc | $45.6M | 5.7% | 3.2M | −97K (−3%) | 8 of 8 | |
| 5 |  PAR Par Technology Corp | $42.1M | 5.3% | 2.4M | −314K (−11%) | 8 of 8 | |
| 6 |  WEAV Weave Communications Inc | $40.7M | 5.1% | 6.8M | −210K (−3%) | 2 of 8 | |
| 7 |  TFX Teleflex Incorporated | $38.7M | 4.8% | 305K | −95K (−24%) | 2 of 8 | |
| 8 |  AIV APARTMENT INVT & MGMT CO | $36.2M | 4.5% | 12.2M | No change | 8 of 8 | |
| 9 |  MAGN Magnera Corp | $32.9M | 4.1% | 2.8M | +40K (+1%) | 7 of 8 | |
| 10 |  OCTV Octave Intelligence PLC Ord Shs CL B | $31.3M | 3.9% | 1.9M | New position | 1 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
 NVRI Enviri Corp | $108M | 5.5M |
 VISN Commscope Hldg Co Inc | $68.5M | 3.8M |
 USAR USA Rare Earth Inc | $35.4M | 2.3M |
 DXYZ Destiny TECH100 Inc | $9.2M | 345K |
 RARE Ultragenyx Pharmaceutical in | $8.4M | 400K |
🔒 Free account: see all 7.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Newtyn Management 13F FAQ
What does Newtyn Management own?
Newtyn Management reported 34 stocks worth $801M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are QDEL (14.5%), Theravance Biopharma Inc (7.3%) and INDV (6.7%). The table above lists every position in the filing (the top 10 without an account).
What did Newtyn Management buy and sell in Q2 2026?
Compared with Q1 2026: 8 new positions, 7 added to, 13 trimmed and 7 sold out. New positions include OCTV, PSIX and XRN. It sold all of NVRI, VISN and USAR.
When will Newtyn Management file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Newtyn Management's portfolio worth?
The Q2 2026 filing reports $801M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.